dallas glp-1 lawsuit Ozempic® NAION Wegovy® Lawsuit | July 2026

When you're navigating the challenges of GLP-1 therapy, you cant afford to guess about your digestive strategy

As soon as I could, I stopped

The mechanism of action of Zepbound involves dual agonism at both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors

Its extremely important to stop these medications well ahead of time to lower your risk of aspiration (breathing in stomach contents) during surgery, as this can be very dangerous, says Garcia-Webb

Ohki T, Isogawa A, Toda N, Tagawa K (2016) Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors

In October 2021, the drug manufacturer submitted a marketing authorisation application to the EMA and a priority review voucher to the US FDA for the regulatory approval of tirzepatide in type 2 diabetes, leading to an expected review time of 8 months from the date of submission [12]